

Ludwig Kappos

List of Publications by Citations

Source: <https://exaly.com/author-pdf/9180474/ludwig-kappos-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

471
papers

51,754
citations

91
h-index

222
g-index

507
ext. papers

61,473
ext. citations

9.5
avg. IF

7.17
L-index

#	Paper	IF	Citations
471	Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. <i>Annals of Neurology</i> , 2011 , 69, 292-302	9.4	6480
470	Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". <i>Annals of Neurology</i> , 2005 , 58, 840-6	9.4	4020
469	A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. <i>New England Journal of Medicine</i> , 2006 , 354, 899-910	59.2	2432
468	Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. <i>Lancet Neurology</i> , The , 2018 , 17, 162-173	24.1	2419
467	A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. <i>New England Journal of Medicine</i> , 2010 , 362, 387-401	59.2	1971
466	Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. <i>New England Journal of Medicine</i> , 2010 , 362, 402-15	59.2	1686
465	Defining the clinical course of multiple sclerosis: the 2013 revisions. <i>Neurology</i> , 2014 , 83, 278-86	6.5	1632
464	Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. <i>New England Journal of Medicine</i> , 2012 , 367, 1098-107	59.2	1216
463	Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2017 , 376, 209-220	59.2	880
462	Oral fingolimod (FTY720) for relapsing multiple sclerosis. <i>New England Journal of Medicine</i> , 2006 , 355, 1124-40	59.2	877
461	Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2017 , 376, 221-234	59.2	858
460	Placebo-controlled multicentre randomised trial of interferon β in treatment of secondary progressive multiple sclerosis. <i>Lancet</i> , The , 1998 , 352, 1491-1497	40	837
459	Randomized trial of oral teriflunomide for relapsing multiple sclerosis. <i>New England Journal of Medicine</i> , 2011 , 365, 1293-303	59.2	662
458	Neurofilaments as biomarkers in neurological disorders. <i>Nature Reviews Neurology</i> , 2018 , 14, 577-589	15	627
457	Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. <i>Nature Genetics</i> , 2009 , 41, 776-82	36.3	621
456	Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Neurology</i> , The , 2014 , 13, 545-56	24.1	572
455	Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. <i>Lancet</i> , The , 2011 , 378, 1779-87	40	522

454	MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines. <i>Lancet Neurology, The</i> , 2016 , 15, 292-303	24.1	486
453	Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis. <i>Annals of Neurology</i> , 2017 , 81, 857-870	9.4	479
452	Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. The Altered Peptide Ligand in Relapsing MS Study Group. <i>Nature Medicine</i> , 2000 , 6, 1176-82	50.5	446
451	Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. <i>Lancet, The</i> , 2018 , 391, 1263-1273	40	422
450	Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. <i>Lancet, The</i> , 2007 , 370, 389-97	40	417
449	Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group. <i>Lancet, The</i> , 1999 , 353, 964-9	40	413
448	Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. <i>Lancet, The</i> , 2008 , 372, 1463-72	40	398
447	Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Neurology, The</i> , 2014 , 13, 247-56	24.1	363
446	Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. <i>Human Molecular Genetics</i> , 2009 , 18, 767-78	5.6	357
445	250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. <i>Lancet Neurology, The</i> , 2009 , 8, 889-97	24.1	338
444	Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis--establishing disease prognosis and monitoring patients. <i>Nature Reviews Neurology</i> , 2015 , 11, 597-606	15	321
443	Vitamin D as an early predictor of multiple sclerosis activity and progression. <i>JAMA Neurology</i> , 2014 , 71, 306-14	17.2	312
442	Pathway and network-based analysis of genome-wide association studies in multiple sclerosis. <i>Human Molecular Genetics</i> , 2009 , 18, 2078-90	5.6	310
441	Placebo-controlled trial of oral laquinimod for multiple sclerosis. <i>New England Journal of Medicine</i> , 2012 , 366, 1000-9	59.2	290
440	ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 96-120	5	286
439	Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. <i>Lancet Neurology, The</i> , 2009 , 8, 987-97	24.1	279
438	Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-clinical implementation in the diagnostic process. <i>Nature Reviews Neurology</i> , 2015 , 11, 471-82	15	272
437	Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2016 , 387, 1075-1084	40	271

436	Increased neurofilament light chain blood levels in neurodegenerative neurological diseases. <i>PLoS ONE</i> , 2013 , 8, e75091	3.7	265
435	Self glycolipids as T-cell autoantigens. <i>European Journal of Immunology</i> , 1999 , 29, 1667-75	6.1	239
434	Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis. <i>JAMA Neurology</i> , 2019 , 76, 1035-1048	17.2	237
433	Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 705-16	5	237
432	Atacept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial. <i>Lancet Neurology</i> , 2014 , 13, 353-63	24.1	212
431	Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. <i>Lancet Neurology</i> , 2011 , 10, 745-58	24.1	212
430	Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis. <i>Brain</i> , 2018 , 141, 2382-2391	11.2	208
429	Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Neurology</i> , 2014 , 13, 977-86	24.1	208
428	Secondary progressive multiple sclerosis: current knowledge and future challenges. <i>Lancet Neurology</i> , 2006 , 5, 343-54	24.1	206
427	Matrix metalloproteinases: multifunctional effectors of inflammation in multiple sclerosis and bacterial meningitis. <i>Brain Research Reviews</i> , 2001 , 36, 249-57		206
426	Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2015 , 373, 1418-28	59.2	203
425	Lack of association between antimyelin antibodies and progression to multiple sclerosis. <i>New England Journal of Medicine</i> , 2007 , 356, 371-8	59.2	197
424	Blood neurofilament light chain as a biomarker of MS disease activity and treatment response. <i>Neurology</i> , 2019 , 92, e1007-e1015	6.5	191
423	Genome-wide association study in a high-risk isolate for multiple sclerosis reveals associated variants in STAT3 gene. <i>American Journal of Human Genetics</i> , 2010 , 86, 285-91	11	188
422	Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. <i>Multiple Sclerosis Journal</i> , 2012 , 18, 143-52	5	186
421	Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. <i>Lancet Neurology</i> , 2011 , 10, 520-9	24.1	178
420	Inclusion of brain volume loss in a revised measure of disease activity (NEDA-4) in relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 1297-305	5	169
419	Altered expression of miR-17-5p in CD4+ lymphocytes of relapsing-remitting multiple sclerosis patients. <i>European Journal of Immunology</i> , 2010 , 40, 888-98	6.1	166

418	The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. <i>Journal of Neurology</i> , 2009 , 256, 405-15	5.5	164
417	Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study. <i>Lancet Neurology, The</i> , 2013 , 12, 756-67	24.1	163
416	Age-dependent B cell autoimmunity to a myelin surface antigen in pediatric multiple sclerosis. <i>Journal of Immunology</i> , 2009 , 183, 4067-76	5.3	161
415	Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. <i>Lancet Neurology, The</i> , 2007 , 6, 431-41	24.1	161
414	Rapamycin attenuates the progression of tau pathology in P301S tau transgenic mice. <i>PLoS ONE</i> , 2013 , 8, e62459	3.7	154
413	Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. <i>Lancet Neurology, The</i> , 2012 , 11, 33-41	24.1	153
412	Long-term effects of fingolimod in multiple sclerosis: the randomized FREEDOMS extension trial. <i>Neurology</i> , 2015 , 84, 1582-91	6.5	148
411	MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study. <i>Neurology</i> , 2014 , 82, 1491-8	6.5	141
410	Grey matter volume in a large cohort of MS patients: relation to MRI parameters and disability. <i>Multiple Sclerosis Journal</i> , 2011 , 17, 1098-106	5	139
409	Analysis of impairment related functional architecture in MS patients during performance of different attention tasks. <i>Journal of Neurology</i> , 2003 , 250, 461-72	5.5	137
408	Health-related quality of life in multiple sclerosis: effects of natalizumab. <i>Annals of Neurology</i> , 2007 , 62, 335-46	9.4	136
407	The alphabeta T cell response to self-glycolipids shows a novel mechanism of CD1b loading and a requirement for complex oligosaccharides. <i>Immunity</i> , 2000 , 13, 255-64	32.3	136
406	The expression profile of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in lesions and normal appearing white matter of multiple sclerosis. <i>Brain</i> , 2001 , 124, 1743-53	11.2	132
405	Ofatumumab versus Teriflunomide in Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2020 , 383, 546-557	59.2	132
404	Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014 , 85, 1190-7	5.5	130
403	Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study. <i>Lancet Neurology, The</i> , 2012 , 11, 420-8	24.1	128
402	Natalizumab: targeting alpha4-integrins in multiple sclerosis. <i>Neurodegenerative Diseases</i> , 2008 , 5, 16-22.3		128
401	Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis. <i>Neurology</i> , 2015 , 84, 1639-43	6.5	119

400	Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management. <i>JAMA Neurology</i> , 2015 , 72, 31-9	17.2	116
399	Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype. <i>Journal of Neuroinflammation</i> , 2015 , 12, 46	10.1	112
398	Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016 , 87, 468-75	5.5	109
397	Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 253-265	5	105
396	Serum neurofilament light chain is a biomarker of human spinal cord injury severity and outcome. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015 , 86, 273-9	5.5	105
395	Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes. <i>Brain</i> , 2015 , 138, 918-31	11.2	103
394	A comparative study of CSF neurofilament light and heavy chain protein in MS. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 1597-603	5	101
393	Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study. <i>Journal of Neurology</i> , 2014 , 261, 267-76	5.5	100
392	Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. <i>Lancet Neurology, The</i> , 2019 , 18, 1021-1033	24.1	98
391	Randomized trial of vaccination in fingolimod-treated patients with multiple sclerosis. <i>Neurology</i> , 2015 , 84, 872-9	6.5	97
390	Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019 , 25, 678-686	5	97
389	Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. <i>Lancet Neurology, The</i> , 2019 , 18, 1009-1020	24.1	96
388	Altered microRNA expression in B lymphocytes in multiple sclerosis: towards a better understanding of treatment effects. <i>Clinical Immunology</i> , 2012 , 144, 70-9	9	96
387	The current role of MRI in differentiating multiple sclerosis from its imaging mimics. <i>Nature Reviews Neurology</i> , 2018 , 14, 199-213	15	95
386	Nonconventional MRI and microstructural cerebral changes in multiple sclerosis. <i>Nature Reviews Neurology</i> , 2015 , 11, 676-86	15	93
385	Correlation between brain volume loss and clinical and MRI outcomes in multiple sclerosis. <i>Neurology</i> , 2015 , 84, 784-93	6.5	93
384	Natalizumab alters transcriptional expression profiles of blood cell subpopulations of multiple sclerosis patients. <i>Journal of Neuroimmunology</i> , 2008 , 194, 153-64	3.5	93
383	Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study. <i>Neurology</i> , 2014 , 83, 78-86	6.5	92

382	Fingolimod in relapsing multiple sclerosis: An integrated analysis of safety findings. <i>Multiple Sclerosis and Related Disorders</i> , 2014 , 3, 494-504	4	91
381	Association of Vitamin D Levels With Multiple Sclerosis Activity and Progression in Patients Receiving Interferon Beta-1b. <i>JAMA Neurology</i> , 2015 , 72, 1458-65	17.2	90
380	Cervical spinal cord volume loss is related to clinical disability progression in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015 , 86, 410-8	5.5	88
379	Working memory training in patients with multiple sclerosis - comparison of two different training schedules. <i>Restorative Neurology and Neuroscience</i> , 2009 , 27, 225-35	2.8	85
378	Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014 , 85, 851-8	5.5	84
377	Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis. <i>Archives of Neurology</i> , 2012 , 69, 1259-69		83
376	Contribution of cortical and white matter lesions to cognitive impairment in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 1290-6	5	82
375	MRI monitoring of pathological changes in the spinal cord in patients with multiple sclerosis. <i>Lancet Neurology, The</i> , 2015 , 14, 443-54	24.1	81
374	Multiple sclerosis as a generalized CNS disease--comparative microarray analysis of normal appearing white matter and lesions in secondary progressive MS. <i>Journal of Neuroimmunology</i> , 2004 , 152, 154-67	3.5	81
373	Long-term safety and efficacy of teriflunomide: Nine-year follow-up of the randomized TEMSO study. <i>Neurology</i> , 2016 , 86, 920-30	6.5	80
372	Dynamic susceptibility contrast MR imaging of plaque development in multiple sclerosis: application of an extended blood-brain barrier leakage correction. <i>Journal of Magnetic Resonance Imaging</i> , 2000 , 11, 495-505	5.6	78
371	The 11-year long-term follow-up study from the randomized BENEFIT CIS trial. <i>Neurology</i> , 2016 , 87, 978-87		78
370	Extraocular blood flow and endothelin-1 plasma levels in patients with multiple sclerosis. <i>European Neurology</i> , 2003 , 49, 164-8	2.1	76
369	Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders. <i>Lancet Neurology, The</i> , 2019 , 18, 185-197	24.1	74
368	Assessing response to interferon-β in a multicenter dataset of patients with MS. <i>Neurology</i> , 2016 , 87, 134-40	6.5	74
367	Prognostic value of copeptin: one-year outcome in patients with acute stroke. <i>Stroke</i> , 2010 , 41, 1564-7	6.7	73
366	Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials. <i>JAMA Neurology</i> , 2020 , 77, 1132-1140	17.2	72
365	Association of regional gray matter volume loss and progression of white matter lesions in multiple sclerosis - A longitudinal voxel-based morphometry study. <i>NeuroImage</i> , 2009 , 45, 60-7	7.9	72

364	Neurofilament light chain serum levels correlate with 10-year MRI outcomes in multiple sclerosis. <i>Annals of Clinical and Translational Neurology</i> , 2018 , 5, 1478-1491	5.3	69
363	MAGNIMS consensus recommendations on the use of brain and spinal cord atrophy measures in clinical practice. <i>Nature Reviews Neurology</i> , 2020 , 16, 171-182	15	68
362	Mannose-binding lectin deficiency is associated with smaller infarction size and favorable outcome in ischemic stroke patients. <i>PLoS ONE</i> , 2011 , 6, e21338	3.7	68
361	A highly sensitive electrochemiluminescence immunoassay for the neurofilament heavy chain protein. <i>Journal of Neuroimmunology</i> , 2010 , 220, 114-9	3.5	68
360	Association Between Serum Neurofilament Light Chain Levels and Long-term Disease Course Among Patients With Multiple Sclerosis Followed up for 12 Years. <i>JAMA Neurology</i> , 2019 , 76, 1359-1366	17.2	67
359	Safety and Efficacy of Siponimod (BAF312) in Patients With Relapsing-Remitting Multiple Sclerosis: Dose-Blinded, Randomized Extension of the Phase 2 BOLD Study. <i>JAMA Neurology</i> , 2016 , 73, 1089-98	17.2	67
358	Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016 , 87, 126-9	5.5	66
357	Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMPO) of oral teriflunomide in relapsing multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2012 , 18, 1625-32	5	66
356	Factors influencing long-term outcomes in relapsing-remitting multiple sclerosis: PRISMS-15. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015 , 86, 1202-7	5.5	65
355	Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis. <i>Brain</i> , 2019 , 142, 2787-2799	11.2	64
354	Strategies for optimizing MRI techniques aimed at monitoring disease activity in multiple sclerosis treatment trials. <i>Journal of Neurology</i> , 1997 , 244, 76-84	5.5	64
353	Delayed-Release Dimethyl Fumarate and Pregnancy: Preclinical Studies and Pregnancy Outcomes from Clinical Trials and Postmarketing Experience. <i>Neurology and Therapy</i> , 2015 , 4, 93-104	4.6	62
352	Neurofilament light chain level is a weak risk factor for the development of MS. <i>Neurology</i> , 2016 , 87, 1076-84	6.5	61
351	The relationship between total and regional corpus callosum atrophy, cognitive impairment and fatigue in multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 356-64	5	60
350	Magnetic resonance imaging outcomes from a phase III trial of teriflunomide. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 1310-9	5	60
349	Evaluation of the Central Vein Sign as a Diagnostic Imaging Biomarker in Multiple Sclerosis. <i>JAMA Neurology</i> , 2019 , 76, 1446-1456	17.2	59
348	Biplanar MRI for the assessment of the spinal cord in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2012 , 18, 1560-9	5	59
347	Antigen-specific adaptive immune responses in fingolimod-treated multiple sclerosis patients. <i>Annals of Neurology</i> , 2011 , 69, 408-13	9.4	59

346	Learning from nature: pregnancy changes the expression of inflammation-related genes in patients with multiple sclerosis. <i>PLoS ONE</i> , 2010 , 5, e8962	3.7	59
345	Endonasal surgery for contact point headaches: a 10-year longitudinal study. <i>Laryngoscope</i> , 2003 , 113, 2151-6	3.6	59
344	Cerebellar abnormalities contribute to disability including cognitive impairment in multiple sclerosis. <i>PLoS ONE</i> , 2014 , 9, e86916	3.7	59
343	Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions. <i>Multiple Sclerosis and Related Disorders</i> , 2016 , 5, 97-104	4	59
342	First-dose effects of fingolimod: Pooled safety data from three phase 3 studies. <i>Multiple Sclerosis and Related Disorders</i> , 2014 , 3, 629-38	4	58
341	Midregional pro-atrial natriuretic peptide and outcome in patients with acute ischemic stroke. <i>Journal of the American College of Cardiology</i> , 2010 , 56, 1045-53	15.1	58
340	Subgroups of the BENEFIT study: risk of developing MS and treatment effect of interferon beta-1b. <i>Journal of Neurology</i> , 2008 , 255, 480-7	5.5	58
339	Measuring and Validating the Levels of Brain-Derived Neurotrophic Factor in Human Serum. <i>ENeuro</i> , 2018 , 5,	3.9	58
338	Effect of BG-12 on contrast-enhanced lesions in patients with relapsing--remitting multiple sclerosis: subgroup analyses from the phase 2b study. <i>Multiple Sclerosis Journal</i> , 2012 , 18, 314-21	5	57
337	Neutralizing antibodies against IFN-beta in multiple sclerosis: antagonization of IFN-beta mediated suppression of MMPs. <i>Brain</i> , 2004 , 127, 259-68	11.2	57
336	Slowly expanding/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesions. <i>Multiple Sclerosis Journal</i> , 2019 , 25, 1915-1925	5	57
335	The hippocampus in multiple sclerosis. <i>Lancet Neurology</i> , 2018 , 17, 918-926	24.1	57
334	Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study. <i>Journal of Neurology</i> , 2014 , 261, 1794-802	5.5	56
333	Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE study. <i>Journal of Neurology</i> , 2013 , 260, 2297-305	5.5	55
332	Advances in oral immunomodulating therapies in relapsing multiple sclerosis. <i>Lancet Neurology</i> , 2020 , 19, 336-347	24.1	54
331	Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS. <i>Journal of Neurology</i> , 2012 , 259, 898-905	5.5	54
330	Teriflunomide slows BVL in relapsing MS: A reanalysis of the TEMSO MRI data set using SIENA. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017 , 4, e390	9.1	53
329	Sodium intake and multiple sclerosis activity and progression in BENEFIT. <i>Annals of Neurology</i> , 2017 , 82, 20-29	9.4	50

328	Dimethyl fumarate influences innate and adaptive immunity in multiple sclerosis. <i>Journal of Autoimmunity</i> , 2018 , 86, 39-50	15.5	50
327	Unraveling treatment response in multiple sclerosis: A clinical and MRI challenge. <i>Neurology</i> , 2019 , 92, 180-192	6.5	50
326	Neurostatus e-Scoring improves consistency of Expanded Disability Status Scale assessments: A proof of concept study. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 597-603	5	48
325	Effect of dimethyl fumarate on lymphocytes in RRMS: Implications for clinical practice. <i>Neurology</i> , 2019 , 92, e1724-e1738	6.5	48
324	Relevance of spinal cord abnormalities to clinical disability in multiple sclerosis: MR imaging findings in a large cohort of patients. <i>Radiology</i> , 2013 , 269, 542-52	20.5	48
323	Abnormal connectivity of the sensorimotor network in patients with MS: a multicenter fMRI study. <i>Human Brain Mapping</i> , 2009 , 30, 2412-25	5.9	47
322	Effects of interferon beta-1b on cognitive performance in patients with a first event suggestive of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2012 , 18, 1466-71	5	47
321	Blood neurofilament light levels segregate treatment effects in multiple sclerosis. <i>Neurology</i> , 2020 , 94, e1201-e1212	6.5	46
320	Fingolimod for multiple sclerosis: mechanism of action, clinical outcomes, and future directions. <i>Current Neurology and Neuroscience Reports</i> , 2011 , 11, 492-7	6.6	46
319	Proton MRS of gadolinium-enhancing MS plaques and metabolic changes in normal-appearing white matter. <i>Magnetic Resonance in Medicine</i> , 1995 , 33, 811-7	4.4	46
318	Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019 , 90, 458-468	5.5	46
317	Quality of life outcomes with BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: the DEFINE study. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 243-52	5	45
316	Neutralising antibodies to interferon beta in multiple sclerosis : expert panel report. <i>Journal of Neurology</i> , 2007 , 254, 827-37	5.5	45
315	Safety and efficacy of amiselimod in relapsing multiple sclerosis (MOMENTUM): a randomised, double-blind, placebo-controlled phase 2 trial. <i>Lancet Neurology</i> , 2016 , 15, 1148-59	24.1	44
314	2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. <i>Lancet Neurology</i> , 2021 , 20, 653-670	24.1	44
313	Radiologically isolated syndrome or subclinical multiple sclerosis: MAGNIMS consensus recommendations. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 214-221	5	43
312	Multiple sclerosis registries in Europe - results of a systematic survey. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 1523-32	5	43
311	Moving toward earlier treatment of multiple sclerosis: Findings from a decade of clinical trials and implications for clinical practice. <i>Multiple Sclerosis and Related Disorders</i> , 2014 , 3, 147-55	4	43

310	Spinal cord volume loss: A marker of disease progression in multiple sclerosis. <i>Neurology</i> , 2018 , 91, e3496-358	43
309	Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. <i>Multiple Sclerosis and Related Disorders</i> , 2019 , 30, 236-243	42
308	Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 963-973	42
307	Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients. <i>Neurology</i> , 2017 , 89, 1584-1593	42
306	Comparative efficacy of switching to natalizumab in active multiple sclerosis. <i>Annals of Clinical and Translational Neurology</i> , 2015 , 2, 373-87	42
305	Dimethyl fumarate for multiple sclerosis. <i>Expert Opinion on Investigational Drugs</i> , 2010 , 19, 1603-12	42
304	Determinants of iron accumulation in deep grey matter of multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 1692-8	41
303	Balance control in multiple sclerosis: correlations of trunk sway during stance and gait tests with disease severity. <i>Gait and Posture</i> , 2013 , 37, 55-60	41
302	Antimyelin antibodies in clinically isolated syndromes correlate with inflammation in MRI and CSF. <i>Journal of Neurology</i> , 2007 , 254, 160-8	41
301	Magnetic resonance imaging effects of interferon beta-1b in the BENEFIT study: integrated 2-year results. <i>Archives of Neurology</i> , 2007 , 64, 1292-8	41
300	On the origin of Neurostatus. <i>Multiple Sclerosis and Related Disorders</i> , 2015 , 4, 182-5	40
299	A phase IIa randomised clinical study of GNBAC1, a humanised monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus in multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 885-93	40
298	Unraveling natalizumab effects on deregulated miR-17 expression in CD4+ T cells of patients with relapsing-remitting multiple sclerosis. <i>Journal of Immunology Research</i> , 2014 , 2014, 897249	40
297	No association of multiple sclerosis activity and progression with EBV or tobacco use in BENEFIT. <i>Neurology</i> , 2015 , 85, 1694-701	39
296	Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP). <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020 , 91, 660-668	39
295	Molecular mechanism underlying the impact of vitamin D on disease activity of MS. <i>Annals of Clinical and Translational Neurology</i> , 2014 , 1, 605-17	39
294	Combined evoked potentials as markers and predictors of disability in early multiple sclerosis. <i>Clinical Neurophysiology</i> , 2012 , 123, 406-10	39
293	Evidence for acute neurotoxicity after chemotherapy. <i>Annals of Neurology</i> , 2010 , 68, 806-15	39

292	Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial. <i>JAMA Neurology</i> , 2021 , 78, 558-567	17.2	39
291	Impact of exposure to interferon beta-1a on outcomes in patients with relapsing-remitting multiple sclerosis: exploratory analyses from the PRISMS long-term follow-up study. <i>Therapeutic Advances in Neurological Disorders</i> , 2011 , 4, 3-14	6.6	38
290	Atrophy is detectable within a 3-month period in untreated patients with active relapsing remitting multiple sclerosis. <i>Archives of Neurology</i> , 2003 , 60, 1736-9		38
289	Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial. <i>Lancet Neurology</i> , 2020 , 19, 998-1009	24.1	38
288	Safety and tolerability profile of daclizumab in patients with relapsing-remitting multiple sclerosis: An integrated analysis of clinical studies. <i>Multiple Sclerosis and Related Disorders</i> , 2016 , 9, 36-46	4	37
287	A comparative analysis of Patient-Reported Expanded Disability Status Scale tools. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 1349-58	5	37
286	Multivariate pattern classification of gray matter pathology in multiple sclerosis. <i>NeuroImage</i> , 2012 , 60, 400-8	7.9	37
285	T cell receptor gamma delta repertoire is skewed in cerebrospinal fluid of multiple sclerosis patients: molecular and functional analyses of antigen-reactive gamma delta clones. <i>European Journal of Immunology</i> , 1995 , 25, 355-63	6.1	36
284	Oculopharyngeal muscular dystrophy - an under-diagnosed disorder?. <i>Swiss Medical Weekly</i> , 2005 , 135, 574-86	3.1	36
283	Combined visual and motor evoked potentials predict multiple sclerosis disability after 20 years. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 1348-54	5	35
282	Spatiotemporal distribution pattern of white matter lesion volumes and their association with regional grey matter volume reductions in relapsing-remitting multiple sclerosis. <i>Human Brain Mapping</i> , 2010 , 31, 1542-55	5.9	35
281	European validation of a standardized clinical description of multiple sclerosis. <i>Journal of Neurology</i> , 2004 , 251, 1472-80	5.5	35
280	Neurofilament light levels are associated with long-term outcomes in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 1691-1699	5	35
279	Cocapture of cognate and bystander antigens can activate autoreactive B cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017 , 114, 734-739	11.5	34
278	Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension. <i>Neurology</i> , 2020 , 95, e1854-e1867	6.5	34
277	A phase IIa randomized clinical study testing GNBAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis associated endogenous retrovirus in multiple sclerosis patients - a twelve month follow-up. <i>Journal of Neuroimmunology</i> , 2015 , 285, 68-70	3.5	33
276	Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 777-785	5	33
275	Short-term and long-term safety and tolerability of interferon β in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2014 , 3, 294-302	4	33

274	Association of Rituximab Treatment With Disability Progression Among Patients With Secondary Progressive Multiple Sclerosis. <i>JAMA Neurology</i> , 2019 , 76, 274-281	17.2	33
273	Electrophysiological markers and predictors of the disease course in primary progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 51-6	5	32
272	Atorvastatin added to interferon β for relapsing multiple sclerosis: a randomized controlled trial. <i>Journal of Neurology</i> , 2012 , 259, 2401-13	5.5	32
271	Incidence and course of depression in multiple sclerosis in the multinational BEYOND trial. <i>Journal of Neurology</i> , 2016 , 263, 1418-26	5.5	32
270	The role of the cerebellum in multiple sclerosis-150 years after Charcot. <i>Neuroscience and Biobehavioral Reviews</i> , 2018 , 89, 85-98	9	31
269	Fingolimod effect on gray matter, thalamus, and white matter in patients with multiple sclerosis. <i>Neurology</i> , 2018 , 90, e1324-e1332	6.5	31
268	Preferential spinal cord volume loss in primary progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019 , 25, 947-957	5	31
267	Extended treatment with fingolimod for relapsing multiple sclerosis: the 14-year LONGTERMS study results. <i>Therapeutic Advances in Neurological Disorders</i> , 2019 , 12, 1756286419878324	6.6	31
266	Magnetization transfer ratio in the delayed-release dimethyl fumarate DEFINE study. <i>Journal of Neurology</i> , 2014 , 261, 2429-37	5.5	31
265	Teriflunomide reduces relapse-related neurological sequelae, hospitalizations and steroid use. <i>Journal of Neurology</i> , 2013 , 260, 2472-80	5.5	31
264	Label-fusion-segmentation and deformation-based shape analysis of deep gray matter in multiple sclerosis: the impact of thalamic subnuclei on disability. <i>Human Brain Mapping</i> , 2014 , 35, 4193-203	5.9	31
263	MiR-126: a novel route for natalizumab action?. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 1363-70	5	31
262	Longitudinal gray matter changes in multiple sclerosis--differential scanner and overall disease-related effects. <i>Human Brain Mapping</i> , 2012 , 33, 1225-45	5.9	31
261	Interleukin 17F level and interferon β response in patients with multiple sclerosis. <i>JAMA Neurology</i> , 2013 , 70, 1017-21	17.2	31
260	The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 520-32	5	30
259	Effect of immunomodulatory medication on regional gray matter loss in relapsing-remitting multiple sclerosis--a longitudinal MRI study. <i>Brain Research</i> , 2010 , 1325, 174-82	3.7	30
258	Preserved antigen-specific immune response in patients with multiple sclerosis responding to IFN β therapy. <i>PLoS ONE</i> , 2013 , 8, e78532	3.7	30
257	Plasma neurofilament light levels are associated with risk of disability in multiple sclerosis. <i>Neurology</i> , 2020 , 94, e2457-e2467	6.5	29

256	Effects of delayed-release dimethyl fumarate (DMF) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: an integrated analysis of the phase 3 DEFINE and CONFIRM studies. <i>Clinical Therapeutics</i> , 2014 , 36, 1958-1971	3.5	29
255	Defining brain volume cutoffs to identify clinically relevant atrophy in RRMS. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 656-664	5	29
254	Serum Neurofilament Light Chain Levels in the Intensive Care Unit: Comparison between Severely Ill Patients with and without Coronavirus Disease 2019. <i>Annals of Neurology</i> , 2021 , 89, 610-616	9.4	29
253	Blood neurofilament light as a potential endpoint in Phase 2 studies in MS. <i>Annals of Clinical and Translational Neurology</i> , 2019 , 6, 1081-1089	5.3	28
252	Power estimation for non-standardized multisite studies. <i>NeuroImage</i> , 2016 , 134, 281-294	7.9	28
251	Clinical effects of natalizumab on multiple sclerosis appear early in treatment course. <i>Journal of Neurology</i> , 2013 , 260, 1388-95	5.5	28
250	Monoclonal antibodies and recombinant immunoglobulins for the treatment of multiple sclerosis. <i>CNS Drugs</i> , 2012 , 26, 11-37	6.7	28
249	Altered functional adaptation to attention and working memory tasks with increasing complexity in relapsing-remitting multiple sclerosis patients. <i>Human Brain Mapping</i> , 2011 , 32, 1704-19	5.9	28
248	Magnetic resonance imaging predictors of conversion to multiple sclerosis in the BENEFIT study. <i>Archives of Neurology</i> , 2009 , 66, 1345-52		28
247	Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial. <i>Multiple Sclerosis Journal</i> , 2012 , 18, 181-95	5	28
246	Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. <i>Journal of Neurology</i> , 2019 , 266, 1182-1193	5.5	28
245	Screening for balance disorders in mildly affected multiple sclerosis patients. <i>Journal of Neurology</i> , 2012 , 259, 1413-9	5.5	27
244	Mental health problems in children of somatically ill parents, e.g. multiple sclerosis. <i>European Child and Adolescent Psychiatry</i> , 2007 , 16, 199-207	5.5	27
243	Siponimod and Cognition in Secondary Progressive Multiple Sclerosis: EXPAND Secondary Analyses. <i>Neurology</i> , 2021 , 96, e376-e386	6.5	26
242	Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus. <i>Journal of Neurology</i> , 2021 , 268, 3961-3968	5.5	26
241	A case of progressive multifocal leukoencephalopathy under dimethyl fumarate treatment without severe lymphopenia or immunosenescence. <i>Multiple Sclerosis Journal</i> , 2019 , 25, 1682-1685	5	25
240	Safety and efficacy of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: 9 years follow-up of DEFINE, CONFIRM, and ENDORSE. <i>Therapeutic Advances in Neurological Disorders</i> , 2020 , 13, 1756286420915005	6.6	25
239	Evaluation of a new approach for semi-automatic segmentation of the cerebellum in patients with multiple sclerosis. <i>Journal of Neurology</i> , 2012 , 259, 2673-80	5.5	25

238	Natalizumab-induced POU2AF1/Spi-B upregulation: A possible route for PML development. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016 , 3, e223	9.1	25
237	Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study. <i>Multiple Sclerosis Journal</i> , 2019 , 25, 1255-1262	5	24
236	Histone deacetylase gene variants predict brain volume changes in multiple sclerosis. <i>Neurobiology of Aging</i> , 2013 , 34, 238-47	5.6	24
235	Progression in disability and regional grey matter atrophy in relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 202-13	5	24
234	3D GRASE arterial spin labelling reveals an inverse correlation of cortical perfusion with the white matter lesion volume in MS. <i>Multiple Sclerosis Journal</i> , 2012 , 18, 1570-6	5	24
233	Pharmacodynamics of interferon beta in multiple sclerosis patients with or without serum neutralizing antibodies. <i>Journal of Neurology</i> , 2007 , 254, 597-604	5.5	24
232	Discrepancies in the interpretation of clinical symptoms and signs in the diagnosis of multiple sclerosis. A proposal for standardization. <i>Multiple Sclerosis Journal</i> , 2005 , 11, 227-31	5	24
231	Subcutaneous interferon β 1a in the treatment of clinically isolated syndromes: 3-year and 5-year results of the phase III dosing frequency-blind multicentre REFLEXION study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017 , 88, 285-294	5.5	23
230	Interleukin 15 stimulates production of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 by human peripheral blood mononuclear cells. <i>Cytokine</i> , 2001 , 13, 244-7	4	23
229	Ocrelizumab in Primary Progressive and Relapsing Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2017 , 376, 1694	59.2	22
228	Fluid biomarker and electrophysiological outcome measures for progressive MS trials. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 1600-1613	5	22
227	Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis. <i>Neurology</i> , 2019 , 93, e1778-e1786	6.5	22
226	Onset of clinical and MRI efficacy occurs early after fingolimod treatment initiation in relapsing multiple sclerosis. <i>Journal of Neurology</i> , 2016 , 263, 354-360	5.5	22
225	Monitoring multiple sclerosis by multimodal evoked potentials: Numerically versus ordinaly scaled scoring systems. <i>Clinical Neurophysiology</i> , 2016 , 127, 1864-71	4.3	22
224	The Swiss Multiple Sclerosis Cohort-Study (SMSC): A Prospective Swiss Wide Investigation of Key Phases in Disease Evolution and New Treatment Options. <i>PLoS ONE</i> , 2016 , 11, e0152347	3.7	22
223	Anti-interferon-beta neutralising activity is not entirely mediated by antibodies. <i>Journal of Neuroimmunology</i> , 2007 , 192, 198-205	3.5	21
222	Atorvastatin added to interferon beta for relapsing multiple sclerosis: 12-month treatment extension of the randomized multicenter SWABIMS trial. <i>PLoS ONE</i> , 2014 , 9, e86663	3.7	21
221	Comparative efficacy of first-line natalizumab vs IFN- β br glatiramer acetate in relapsing MS. <i>Neurology: Clinical Practice</i> , 2016 , 6, 102-115	1.7	21

220	Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial. <i>Annals of Neurology</i> , 2018 , 84, 527-536	9.4	21
219	Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study. <i>Journal of Neurology</i> , 2014 , 261, 1781-8	5.5	20
218	Cognitive rehabilitation of working memory in juvenile multiple sclerosis-effects on cognitive functioning, functional MRI and network related connectivity. <i>Restorative Neurology and Neuroscience</i> , 2015 , 33, 713-25	2.8	20
217	Spatiotemporal distribution of white matter lesions in relapsing-remitting and secondary progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2012 , 18, 1577-84	5	20
216	The distribution of magnetic resonance imaging response to interferonbeta-1b in multiple sclerosis. <i>Journal of Neurology</i> , 2005 , 252, 1455-8	5.5	20
215	Damage of the lateral geniculate nucleus in MS: Assessing the missing node of the visual pathway. <i>Neurology</i> , 2019 , 92, e2240-e2249	6.5	19
214	No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2018 , 4, 2055217318760642	2	19
213	Two-year results from a phase 2 extension study of oral amiselimod in relapsing multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 1605-1616	5	19
212	Retraining attention in MS. <i>Journal of the Neurological Sciences</i> , 2006 , 245, 147-51	3.2	19
211	Subcortical brain segmentation of two dimensional T1-weighted data sets with FMRIB's Integrated Registration and Segmentation Tool (FIRST). <i>NeuroImage: Clinical</i> , 2015 , 7, 43-52	5.3	18
210	α -integrin receptor desaturation and disease activity return after natalizumab cessation. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017 , 4, e388	9.1	18
209	Glutamate gene polymorphisms predict brain volumes in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 281-8	5	18
208	Performance of five research-domain automated WM lesion segmentation methods in a multi-center MS study. <i>NeuroImage</i> , 2017 , 163, 106-114	7.9	18
207	Case-Based fMRI Analysis after Cognitive Rehabilitation in MS: A Novel Approach. <i>Frontiers in Neurology</i> , 2015 , 6, 78	4.1	18
206	Ocrelizumab in relapsing and primary progressive multiple sclerosis: Pharmacokinetic and pharmacodynamic analyses of OPERA I, OPERA II and ORATORIO. <i>British Journal of Clinical Pharmacology</i> , 2021 , 87, 2511-2520	3.8	18
205	Multiple sclerosis relapses are associated with increased fatigue and reduced health-related quality of life - A post hoc analysis of the TEMSO and TOWER studies. <i>Multiple Sclerosis and Related Disorders</i> , 2016 , 7, 33-40	4	17
204	Interferon beta-1b reduces black holes in a randomised trial of clinically isolated syndrome. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 234-42	5	17
203	Fatal vascular leak syndrome with extensive hemorrhage, peripheral neuropathy and reactive erythrophagocytosis: an unusual complication of recombinant IL-3 therapy. <i>Leukemia and Lymphoma</i> , 1996 , 20, 337-40	1.9	17

202	Usability and Acceptability of ASSESS MS: Assessment of Motor Dysfunction in Multiple Sclerosis Using Depth-Sensing Computer Vision. <i>JMIR Human Factors</i> , 2015 , 2, e11	2.5	17
201	Quantifying progression of multiple sclerosis via classification of depth videos. <i>Lecture Notes in Computer Science</i> , 2014 , 17, 429-37	0.9	17
200	Radiologic MS disease activity during natalizumab treatment interruption: findings from RESTORE. <i>Journal of Neurology</i> , 2015 , 262, 326-36	5.5	16
199	Efficacy of subcutaneous interferon β 1a on MRI outcomes in a randomised controlled trial of patients with clinically isolated syndromes. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014 , 85, 647-53	5.5	16
198	Teriflunomide for oral therapy in multiple sclerosis. <i>Expert Review of Clinical Pharmacology</i> , 2012 , 5, 617-38		16
197	Cervical dystonia as first manifestation of multiple sclerosis. <i>Journal of Neurology</i> , 2004 , 251, 1408-10	5.5	16
196	Efficacy and Safety of Fingolimod in an Unselected Patient Population. <i>PLoS ONE</i> , 2016 , 11, e0146190	3.7	16
195	Multiple Sclerosis and Antibodies against KIR4.1. <i>New England Journal of Medicine</i> , 2016 , 374, 1496-8	59.2	16
194	Monitoring of radiologic disease activity by serum neurofilaments in MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020 , 7,	9.1	16
193	Clinical Correlations of Brain Lesion Location in Multiple Sclerosis: Voxel-Based Analysis of a Large Clinical Trial Dataset. <i>Brain Topography</i> , 2018 , 31, 886-894	4.3	16
192	Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study.. <i>Lancet Neurology, The</i> , 2022 , 21, 246-257	24.1	16
191	No evidence of disease activity in patients receiving daclizumab versus intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis in the DECIDE study. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 1736-1747	5	15
190	Long-term results from a phase 2 extension study of fingolimod at high and approved dose in relapsing multiple sclerosis. <i>Journal of Neurology</i> , 2015 , 262, 2627-34	5.5	15
189	Volume loss in the deep gray matter and thalamic subnuclei: a longitudinal study on disability progression in multiple sclerosis. <i>Journal of Neurology</i> , 2020 , 267, 1536-1546	5.5	15
188	Evolution of MS lesions to black holes under DNA vaccine treatment. <i>Journal of Neurology</i> , 2012 , 259, 1375-82	5.5	15
187	Myelin and axon pathology in multiple sclerosis assessed by myelin water and multi-shell diffusion imaging. <i>Brain</i> , 2021 , 144, 1684-1696	11.2	15
186	Magnetization transfer ratio in lesions rather than normal-appearing brain relates to disability in patients with multiple sclerosis. <i>Journal of Neurology</i> , 2015 , 262, 1909-17	5.5	14
185	Aggressive multiple sclerosis (1): Towards a definition of the phenotype. <i>Multiple Sclerosis Journal</i> , 2020 , 1352458520925369	5	14

184	Longitudinal patterns of cortical thinning in multiple sclerosis. <i>Human Brain Mapping</i> , 2020 , 41, 2198-2215	5.9	14
183	SUMMIT (Serially Unified Multicenter Multiple Sclerosis Investigation): creating a repository of deeply phenotyped contemporary multiple sclerosis cohorts. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 1485-1498	5.1	14
182	Immunologic monitoring during a phase 2a trial of the GNBAC1 antibody in patients with MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015 , 2, e144	9.1	14
181	Chronic White Matter Inflammation and Serum Neurofilament Levels in Multiple Sclerosis. <i>Neurology</i> , 2021 , 97, e543-e553	6.5	14
180	MRI-based prediction of conversion from clinically isolated syndrome to clinically definite multiple sclerosis using SVM and lesion geometry. <i>Brain Imaging and Behavior</i> , 2019 , 13, 1361-1374	4.1	14
179	A comparison of brain magnetic resonance imaging lesions in multiple sclerosis by race with reference to disability progression. <i>Journal of Neuroinflammation</i> , 2018 , 15, 255	10.1	14
178	Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis. <i>Neurology</i> , 2021 , 97, e1546-e1559	6.5	14
177	Brain atrophy and disability worsening in primary progressive multiple sclerosis: insights from the INFORMS study. <i>Annals of Clinical and Translational Neurology</i> , 2018 , 5, 346-356	5.3	13
176	Multicenter R2* mapping in the healthy brain. <i>Magnetic Resonance in Medicine</i> , 2014 , 71, 1103-7	4.4	13
175	Interferon-beta antibodies: implications for the treatment of MS. <i>Lancet Neurology</i> , 2003 , 2, 528	24.1	13
174	Competing interests in multiple sclerosis research. <i>Lancet, The</i> , 2003 , 361, 350-1	4.0	13
173	Laquinimod Safety Profile: Pooled Analyses from the ALLEGRO and BRAVO Trials. <i>International Journal of MS Care</i> , 2017 , 19, 16-24	2.3	13
172	Long-term outcomes with teriflunomide in patients with clinically isolated syndrome: Results of the TOPIC extension study. <i>Multiple Sclerosis and Related Disorders</i> , 2019 , 33, 131-138	4	12
171	Optimizing treatment initiation: Effects of a patient education program about fingolimod treatment on knowledge, self-efficacy and patient satisfaction. <i>Multiple Sclerosis and Related Disorders</i> , 2015 , 4, 444-450	4	12
170	Safety of teriflunomide for the management of relapsing-remitting multiple sclerosis. <i>Expert Opinion on Drug Safety</i> , 2015 , 14, 749-59	4.1	12
169	Severe exacerbation of relapsing-remitting multiple sclerosis after G-CSF therapy. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016 , 3, e215	9.1	12
168	Patient subgroup analyses of the treatment effect of subcutaneous interferon β 1a on development of multiple sclerosis in the randomized controlled REFLEX study. <i>Journal of Neurology</i> , 2014 , 261, 490-9	5.5	12
167	Immune-mediated neuropathies: etiology and pathogenic relationship to aging processes. <i>Journal of Neuroimmunology</i> , 2003 , 137, 1-11	3.5	12

166	Quantitative magnetic resonance imaging towards clinical application in multiple sclerosis. <i>Brain</i> , 2021 , 144, 1296-1311	11.2	12
165	Reliable volumetry of the cervical spinal cord in MS patient follow-up data with cord image analyzer (Cordial). <i>Journal of Neurology</i> , 2016 , 263, 1364-74	5.5	12
164	Association of brain volume loss and long-term disability outcomes in patients with multiple sclerosis treated with teriflunomide. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 1207-1216	5	12
163	Presence of SARS-CoV-2 Transcripts in the Choroid Plexus of MS and Non-MS Patients With COVID-19. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021 , 8,	9.1	12
162	Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting. <i>Multiple Sclerosis and Related Disorders</i> , 2018 , 24, 11-19	4	12
161	The efficacy of teriflunomide in patients who received prior disease-modifying treatments: Subgroup analyses of the teriflunomide phase 3 TEMSO and TOWER studies. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 535-539	5	11
160	Improved characterization of visual evoked potentials in multiple sclerosis by topographic analysis. <i>Brain Topography</i> , 2014 , 27, 318-27	4.3	11
159	Impact of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod: Subgroup analyses of the Fingolimod Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) study. <i>Multiple Sclerosis and Related Disorders</i> , 2014 , 3, 341-9	4	11
158	Transcriptional profiling of multiple sclerosis: towards improved diagnosis and treatment. <i>Expert Review of Molecular Diagnostics</i> , 2006 , 6, 843-55	3.8	11
157	Development of multiple sclerosis in patient on long-term sulfasalazine. <i>Lancet, The</i> , 1990 , 335, 409-10	4.0	11
156	An attempt to quantify magnetic resonance imaging in multiple sclerosis--correlation with clinical parameters. <i>Neurosurgical Review</i> , 1987 , 10, 133-5	3.9	11
155	Interdisciplinary Risk Management in the Treatment of Multiple Sclerosis. <i>Deutsches A&#x0308;rzteblatt International</i> , 2016 , 113, 879-886	2.5	11
154	Long-term prognostic value of longitudinal measurements of blood neurofilament levels. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020 , 7,	9.1	11
153	Diagnosis of Progressive Multiple Sclerosis From the Imaging Perspective: A Review. <i>JAMA Neurology</i> , 2021 , 78, 351-364	17.2	11
152	Learning ability correlates with brain atrophy and disability progression in RRMS. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019 , 90, 38-43	5.5	11
151	Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy. <i>Journal of the Neurological Sciences</i> , 2018 , 391, 72-76	3.2	11
150	Accurate, rapid and reliable, fully automated MRI brainstem segmentation for application in multiple sclerosis and neurodegenerative diseases. <i>Human Brain Mapping</i> , 2019 , 40, 4091-4104	5.9	10
149	MRI characteristics of periaqueductal lesions in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2014 , 3, 542-51	4	10

148	Non-communicating syringomyelia: a feature of spinal cord involvement in multiple sclerosis. <i>Brain</i> , 2008 , 131, 1776-82	11.2	10
147	Alternatives to current disease-modifying treatment in MS: what do we need and what can we expect in the future?. <i>Journal of Neurology</i> , 2004 , 251 Suppl 5, v57-v64	5.5	10
146	Vitamin D, smoking, EBV, and long-term cognitive performance in MS: 11-year follow-up of BENEFIT. <i>Neurology</i> , 2020 , 94, e1950-e1960	6.5	10
145	Antigen Extraction and B Cell Activation Enable Identification of Rare Membrane Antigen Specific Human B Cells. <i>Frontiers in Immunology</i> , 2019 , 10, 829	8.4	9
144	Delayed-release dimethyl fumarate and disability assessed by the Multiple Sclerosis Functional Composite: Integrated analysis of DEFINE and CONFIRM. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2016 , 2, 2055217316634111	2	9
143	Global N-acetylaspartate concentration in benign and non-benign multiple sclerosis patients of long disease duration. <i>European Journal of Radiology</i> , 2013 , 82, e848-52	4.7	9
142	Design and construction of an innovative brain phantom prototype for MRI. <i>Magnetic Resonance in Medicine</i> , 2019 , 81, 1165-1171	4.4	9
141	Association of antibodies against myelin and neuronal antigens with neuroinflammation in systemic lupus erythematosus. <i>Rheumatology</i> , 2019 , 58, 908-913	3.9	9
140	Reduced accuracy of MRI deep grey matter segmentation in multiple sclerosis: an evaluation of four automated methods against manual reference segmentations in a multi-center cohort. <i>Journal of Neurology</i> , 2020 , 267, 3541-3554	5.5	8
139	Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 1564-1576	5	8
138	Delay from treatment start to full effect of immunotherapies for multiple sclerosis. <i>Brain</i> , 2020 , 143, 2742-2756	11.2	8
137	Individual Assessment of Brain Tissue Changes in MS and the Effect of Focal Lesions on Short-Term Focal Atrophy Development in MS: A Voxel-Guided Morphometry Study. <i>International Journal of Molecular Sciences</i> , 2016 , 17, 489	6.3	8
136	Shortening the washout to 4 weeks when switching from natalizumab to fingolimod and risk of disease reactivation in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2018 , 25, 14-20	4	7
135	Automatic Spinal Cord Gray Matter Quantification: A Novel Approach. <i>American Journal of Neuroradiology</i> , 2019 , 40, 1592-1600	4.4	7
134	Clinical trials in multiple sclerosis. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2014 , 122, 445-53	3	7
133	Efficacy and safety of interferon beta-1b sc in older RRMS patients--a posthoc analysis of the BEYOND study. <i>Journal of Neurology</i> , 2013 , 260, 1838-45	5.5	7
132	Consistent efficacy of daclizumab beta across patient demographic and disease activity subgroups in patients with relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2017 , 17, 32-40	4	7
131	Lesion-to-ventricle distance and other risk factors for the persistence of newly formed black holes in relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 322-30	5	7

130	Clinical trials of immunosuppression and immunomodulation in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 1988 , 20, 261-8	3.5	7
129	Long-term safety and efficacy of teriflunomide in patients with relapsing multiple sclerosis: Results from the TOWER extension study. <i>Multiple Sclerosis and Related Disorders</i> , 2020 , 46, 102438	4	7
128	PARP-1 deregulation in multiple sclerosis. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2019 , 5, 2055217319894604	2	7
127	Comparative analysis of dimethyl fumarate and fingolimod in relapsing-remitting multiple sclerosis. <i>Journal of Neurology</i> , 2021 , 268, 941-949	5.5	7
126	Long-term safety and efficacy of dimethyl fumarate for up to 13 years in patients with relapsing-remitting multiple sclerosis: Final ENDORSE study results. <i>Multiple Sclerosis Journal</i> , 2021 , 1352458521103790	5	7
125	The role of cerebellar abnormalities in neuromyelitis optica--a comparison with multiple sclerosis and healthy controls. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 757-66	5	6
124	10 years of interferon beta-1b (Beta feron therapy. <i>Journal of Neurology</i> , 2005 , 252 Suppl 3, iii1-iii2	5.5	6
123	Genomics and proteomics: role in the management of multiple sclerosis. <i>Journal of Neurology</i> , 2005 , 252 Suppl 3, iii21-iii27	5.5	6
122	Combinations of drugs. <i>Multiple Sclerosis Journal</i> , 1996 , 1, 400-3	5	6
121	Risk of requiring a wheelchair in primary progressive multiple sclerosis: Data from the ORATORIO trial and the MSBase registry. <i>European Journal of Neurology</i> , 2021 ,	6	6
120	Intrathecal Immunoglobulin M Synthesis is an Independent Biomarker for Higher Disease Activity and Severity in Multiple Sclerosis. <i>Annals of Neurology</i> , 2021 , 90, 477-489	9.4	6
119	Relapses Requiring Intravenous Steroid Use and Multiple-Sclerosis-related Hospitalizations: Integrated Analysis of the Delayed-release Dimethyl Fumarate Phase III Studies. <i>Clinical Therapeutics</i> , 2015 , 37, 2543-51	3.5	5
118	Xenogeneic Neu5Gc and self-glycan Neu5Ac epitopes are potential immune targets in MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020 , 7,	9.1	5
117	Quantified CSF antibody reactivity against myelin in multiple sclerosis. <i>Annals of Clinical and Translational Neurology</i> , 2015 , 2, 1116-23	5.3	5
116	Avidity of vaccine-induced influenza IgG fails to increase in fingolimod-treated patients with MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2014 , 1, e28	9.1	5
115	Alemtuzumab for multiple sclerosis: who and when to treat?. <i>Lancet, The</i> , 2012 , 380, 1795-7	40	5
114	Images in clinical medicine. Dissociation of voluntary and emotional innervation after stroke. <i>New England Journal of Medicine</i> , 2010 , 363, e25	59.2	5
113	Interferons in multiple sclerosis. <i>Neurologic Clinics</i> , 2005 , 23, 189-214, vii-viii	4.5	5

112	The Janus face of CNS-directed autoimmune response: a therapeutic challenge. <i>Brain</i> , 2002 , 125, 2379-80	1.2	5
111	Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial. <i>Lancet Neurology</i> , 2021 , 20, 1001-1011	24.1	5
110	Epoch Analysis of On-Treatment Disability Progression Events over Time in the Tysabri Observational Program (TOP). <i>PLoS ONE</i> , 2016 , 11, e0144834	3.7	5
109	Prognostic factors for long-term outcomes in relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2016 , 2, 2055217316666406	2	5
108	Hepatitis E virus infections in patients with MS on oral disease-modifying treatment. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019 , 6,	9.1	5
107	New and enlarging white matter lesions adjacent to the ventricle system and thalamic atrophy are independently associated with lateral ventricular enlargement in multiple sclerosis. <i>Journal of Neurology</i> , 2020 , 267, 192-202	5.5	5
106	Clinical outcomes in patients who discontinue natalizumab therapy after 2 years in the Tysabri Observational Program (TOP). <i>Multiple Sclerosis Journal</i> , 2021 , 27, 410-419	5	5
105	Clinical associations of T2-weighted lesion load and lesion location in small vessel disease: Insights from a large prospective cohort study. <i>NeuroImage</i> , 2019 , 189, 727-733	7.9	4
104	Predictors of disease activity in 857 patients with MS treated with interferon beta-1b. <i>Journal of Neurology</i> , 2015 , 262, 2466-71	5.5	4
103	Levels of brain-derived neurotrophic factor in patients with multiple sclerosis. <i>Annals of Clinical and Translational Neurology</i> , 2020 , 7, 2251-2261	5.3	4
102	Growth differentiation factor 15 is increased in stable MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020 , 7,	9.1	4
101	Comparison between balanced steady-state free precession and standard spoiled gradient echo magnetization transfer ratio imaging in multiple sclerosis: methodical and clinical considerations. <i>NeuroImage</i> , 2015 , 108, 87-94	7.9	4
100	Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trials. <i>Multiple Sclerosis Journal</i> , 2019 , 25, 565-573	5	4
99	Electronic Neurostatus-EDSS increases the quality of expanded disability status scale assessments: Experience from two phase 3 clinical trials. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 993-996	5	4
98	Real-world disability improvement in patients with relapsing-remitting multiple sclerosis treated with natalizumab in the Tysabri Observational Program. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 719-728	5	4
97	Fingolimod in children with Rett syndrome: the FINGORETT study. <i>Orphanet Journal of Rare Diseases</i> , 2021 , 16, 19	4.2	4
96	PML risk and natalizumab: the elephant in the room. <i>Lancet Neurology</i> , 2017 , 16, 864-865	24.1	3
95	Hereditary defect of cobalamin metabolism with adolescence onset resembling multiple sclerosis: 41-year follow up in two cases. <i>Therapeutic Advances in Neurological Disorders</i> , 2019 , 12, 1756286419872115	6.6	3

94	Facial nerve palsy and anti-Ku autoantibodies. <i>Journal of Neurology</i> , 2012 , 259, 361-3	5.5	3
93	Expression of the B cell-associated tyrosine kinase gene Lyn in primary neuroblastoma tumours and its modulation during the differentiation of neuroblastoma cell lines. <i>Biochemical and Biophysical Research Communications</i> , 1992 , 186, 1403-9	3.4	3
92	Impact of informative censoring on the treatment effect estimate of disability worsening in multiple sclerosis clinical trials. <i>Multiple Sclerosis and Related Disorders</i> , 2019 , 39, 101865	4	3
91	Artificial intelligence extension of the OSCAR-IB criteria. <i>Annals of Clinical and Translational Neurology</i> , 2021 , 8, 1528-1542	5.3	3
90	Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: Data from the OPERA I and OPERA II trials. <i>European Journal of Neurology</i> , 2021 ,	6	3
89	Ozanimod in relapsing multiple sclerosis: Pooled safety results from the clinical development program. <i>Multiple Sclerosis and Related Disorders</i> , 2021 , 51, 102844	4	3
88	Tasks of activities of daily living (ADL) are more valuable than the classical neurological examination to assess upper extremity function and mobility in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019 , 25, 1673-1681	5	3
87	Short timescale modulation of cortical and cerebellar activity in the early phase of motor sequence learning: an fMRI study. <i>Brain Imaging and Behavior</i> , 2020 , 14, 2159-2175	4.1	3
86	Effect of Ozanimod on Symbol Digit Modalities Test Performance in Relapsing MS. <i>Multiple Sclerosis and Related Disorders</i> , 2021 , 48, 102673	4	3
85	Standardization and digitization of clinical data in multiple sclerosis. <i>Nature Reviews Neurology</i> , 2021 , 17, 119-125	15	3
84	Classification of multiple sclerosis based on patterns of CNS regional atrophy covariance. <i>Human Brain Mapping</i> , 2021 , 42, 2399-2415	5.9	3
83	Central Slab versus Whole Brain to Measure Brain Atrophy in Multiple Sclerosis. <i>European Neurology</i> , 2018 , 80, 207-214	2.1	3
82	061 Ocrelizumab reduces disability progression independent of relapse activity in patients with relapsing multiple sclerosis (RMS) (ENCORE). <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018 , 89, A25.2-A25	5.5	3
81	Sustained reduction of serum neurofilament light chain over 7 years by alemtuzumab in early relapsing-remitting MS. <i>Multiple Sclerosis Journal</i> , 2021 , 13524585211032348	5	3
80	No consensus about consensus?. <i>Neurological Research and Practice</i> , 2021 , 3, 46	3.2	3
79	Central nervous system atrophy predicts future dynamics of disability progression in a real-world multiple sclerosis cohort. <i>European Journal of Neurology</i> , 2021 , 28, 4153-4166	6	3
78	Immunological predictors of dimethyl fumarate-induced lymphopenia.. <i>Annals of Neurology</i> , 2022 ,	9.4	3
77	White matter lesion location correlates with disability in relapsing multiple sclerosis. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2020 , 6, 2055217320906844	2	2

76	Efficacy of inpatient personalized multidisciplinary rehabilitation in multiple sclerosis: behavioural and functional imaging results. <i>Journal of Neurology</i> , 2020 , 267, 1744-1753	5.5	2
75	Efficacy of daclizumab beta versus intramuscular interferon beta-1a on disability progression across patient demographic and disease activity subgroups in DECIDE. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 1883-1891	5	2
74	Reference videos reduce variability of motor dysfunction assessments in multiple sclerosis. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2018 , 4, 2055217318792399	2	2
73	Reporting of subgroup analyses from clinical trials [Author's reply]. <i>Lancet Neurology</i> , 2012 , 11, 747-748	2.1	2
72	Detection of cerebrospinal fluid leaks by intrathecal contrast-enhanced magnetic resonance myelography. <i>JAMA Neurology</i> , 2013 , 70, 1576-7	17.2	2
71	Optimizing brain MRI protocols in the follow-up of patients with multiple sclerosis T2-weighted MRI of the brain after the administration of gadopentetate dimeglumine. <i>Magnetic Resonance Imaging</i> , 2005 , 23, 469-74	3.3	2
70	Bundle Myelin Fraction (BMF) Mapping of Different White Matter Connections Using Microstructure Informed Tractography.. <i>NeuroImage</i> , 2022 , 118922	7.9	2
69	Measuring treatment response to advance precision medicine for multiple sclerosis. <i>Annals of Clinical and Translational Neurology</i> , 2021 , 8, 2166-2173	5.3	2
68	Video-Based Pairwise Comparison: Enabling the Development of Automated Rating of Motor Dysfunction in Multiple Sclerosis. <i>Archives of Physical Medicine and Rehabilitation</i> , 2020 , 101, 234-241	2.8	2
67	Evolution of Cortical and White Matter Lesion Load in Early-Stage Multiple Sclerosis: Correlation With Neuroaxonal Damage and Clinical Changes. <i>Frontiers in Neurology</i> , 2020 , 11, 973	4.1	2
66	Disability improvement as a clinically relevant outcome in clinical trials of relapsing forms of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 2219-2231	5	2
65	Practice Effects of Mobile Tests of Cognition, Dexterity, and Mobility on Patients With Multiple Sclerosis: Data Analysis of a Smartphone-Based Observational Study. <i>Journal of Medical Internet Research</i> , 2021 , 23, e30394	7.6	2
64	Disability progression multiple sclerosis patients on fingolimod versus interferon-beta/glatiramer acetate. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 439-448	5	2
63	The introduction of new medications in pediatric multiple sclerosis: Open issues and challenges. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 479-482	5	2
62	Combination of teriflunomide and interferon as follow-up therapy after fingolimod-associated PML. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021 , 8,	9.1	2
61	Serum neurofilament light chain as outcome marker for intensive care unit patients. <i>Journal of Neurology</i> , 2021 , 268, 1323-1329	5.5	2
60	Imaging multiple sclerosis pathology at 160 μ m isotropic resolution by human whole-brain ex vivo magnetic resonance imaging at 3T. <i>Scientific Reports</i> , 2021 , 11, 15491	4.9	2
59	Plasma neurofilament light chain concentrations as a biomarker of clinical and radiologic outcomes in relapsing multiple sclerosis: Post hoc analysis of Phase 3 ozanimod trials. <i>European Journal of Neurology</i> , 2021 , 28, 3722-3730	6	2

58	Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression. <i>Computer Methods and Programs in Biomedicine</i> , 2021 , 208, 106180	6.9	2
57	No evidence for loss of natalizumab effectiveness with every-6-week dosing: a propensity score-matched comparison with every-4-week dosing in patients enrolled in the Tysabri Observational Program (TOP). <i>Therapeutic Advances in Neurological Disorders</i> , 2021 , 14, 17562864211042458	6.6	2
56	Self glycolipids as T-cell autoantigens 1999 , 29, 1667		2
55	Re: Neutralizing antibodies to interferon beta-1b are not associated with disease worsening in multiple sclerosis. <i>Journal of International Medical Research</i> , 2008 , 36, 204-8; author reply 208-10	1.4	2
54	Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: Gray matter atrophy and magnetization transfer ratio analyses from the EXPAND phase 3 trial.. <i>Multiple Sclerosis Journal</i> , 2022 , 13524585221076717	5	2
53	Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 years.. <i>Multiple Sclerosis Journal</i> , 2022 , 13524585221083194	5	2
52	Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study. <i>Journal of Neurology</i> ,	5.5	2
51	PML with dimethyl fumarate-No convincing case against natalizumab. <i>Multiple Sclerosis Journal</i> , 2019 , 25, 1687-1688	5	1
50	Mitochondrial cytopathy with common MELAS mutation presenting as multiple system atrophy mimic. <i>Neurology: Genetics</i> , 2016 , 2, e121	3.8	1
49	DACLIZUMAB HYP VS IM INTERFERON BETA-1A IN MS: NEDA RESULTS FROM DECIDE. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016 , 87, e1.47-e1	5.5	1
48	Preliminary results of the opera i and opera ii open-label extension study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017 , 88, e1.90-e1	5.5	1
47	PO129 Neda analysis by epoch in the opera studies of ocrelizumab. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017 , 88, A46.2-A46	5.5	1
46	A confusing patient's history: small or large vessel vasculitis?. <i>Rheumatology International</i> , 2010 , 30, 1681-8	3.8	1
45	New aspects in the treatment of multiple sclerosis with interferon beta-1b. <i>Journal of Neurology</i> , 2004 , 251, iv1	5.5	1
44	Additive and interaction effects of working memory and motor sequence training on brain functional connectivity. <i>Scientific Reports</i> , 2021 , 11, 23089	4.9	1
43	Body mass index as a predictor of MS activity and progression among participants in BENEFIT.. <i>Multiple Sclerosis Journal</i> , 2022 , 13524585211061861	5	1
42	Autoencoder as a New Method for Maintaining Data Privacy While Analyzing Videos of Patients With Motor Dysfunction: Proof-of-Concept Study. <i>Journal of Medical Internet Research</i> , 2020 , 22, e16669	7.6	1
41	Development, validation and clinical usefulness of a prognostic model for relapse in relapsing-remitting multiple sclerosis. <i>Diagnostic and Prognostic Research</i> , 2021 , 5, 17	5.5	1

40	No evidence of disease activity status in patients treated with early vs. delayed subcutaneous interferon β 1a. <i>Multiple Sclerosis and Related Disorders</i> , 2019 , 39, 101891	4	1
39	GAMER-MRI in Multiple Sclerosis Identifies the Diffusion-Based Microstructural Measures That Are Most Sensitive to Focal Damage: A Deep-Learning-Based Analysis and Clinico-Biological Validation. <i>Frontiers in Neuroscience</i> , 2021 , 15, 647535	5.1	1
38	MAGNIMS score predicts long-term clinical disease activity-free status and confirmed disability progression in patients treated with subcutaneous interferon beta-1a. <i>Multiple Sclerosis and Related Disorders</i> , 2021 , 49, 102790	4	1
37	Setwise comparison: efficient fine-grained rating of movement videos using algorithmic support - a proof of concept study. <i>Disability and Rehabilitation</i> , 2020 , 42, 2640-2646	2.4	1
36	The ACROSS study: Long-term efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2020 , 6, 2055217320907951 ²		1
35	Impact of complement activation on clinical outcomes in multiple sclerosis. <i>Annals of Clinical and Translational Neurology</i> , 2021 , 8, 944-950	5.3	1
34	Quantification of Cervical Cord Cross-Sectional Area: Which Acquisition, Vertebra Level, and Analysis Software? A Multicenter Repeatability Study on a Traveling Healthy Volunteer. <i>Frontiers in Neurology</i> , 2021 , 12, 693333	4.1	1
33	Regional Cerebellar Volume Loss Predicts Future Disability in Multiple Sclerosis Patients. <i>Cerebellum</i> , 2021 , 1	4.3	1
32	Microstructure-Weighted Connectomics in Multiple Sclerosis. <i>Brain Connectivity</i> , 2021 ,	2.7	1
31	GAMER MRI: Gated-attention mechanism ranking of multi-contrast MRI in brain pathology. <i>NeuroImage: Clinical</i> , 2021 , 29, 102522	5.3	1
30	The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021.. <i>Multiple Sclerosis Journal</i> , 2022 , 13524585211069068	5	1
29	Multiple Sclerosis Relapses Following Cessation of Fingolimod.. <i>Clinical Drug Investigation</i> , 2022 , 42, 3553.2	3.2	1
28	Prognostic Value of Serum Neurofilament Light Chain for Disease Activity and Worsening in Patients With Relapsing Multiple Sclerosis: Results From the Phase 3 ASCLEPIOS I and II Trials.. <i>Frontiers in Immunology</i> , 2022 , 13, 852563	8.4	1
27	Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II.. <i>Multiple Sclerosis Journal</i> , 2022 , 13524585221078825	5	1
26	Laminar analysis of the cerebellar cortex shows widespread damage in early MS patients: A pilot study at 7T MRI. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2020 , 6, 20552173209361409 ⁰		0
25	Biomarkers of treatment response in patients with progressive multiple sclerosis treated with high-dose pharmaceutical-grade biotin (MD1003). <i>Brain and Behavior</i> , 2021 , 11, e01998	3.4	0
24	Development and evaluation of a manual segmentation protocol for deep grey matter in multiple sclerosis: Towards accelerated semi-automated references. <i>NeuroImage: Clinical</i> , 2021 , 30, 102659	5.3	0
23	Safety and efficacy of daclizumab beta in patients with relapsing multiple sclerosis in a 5-year open-label study (EXTEND): final results following early termination. <i>Therapeutic Advances in Neurological Disorders</i> , 2021 , 14, 1756286420987941	6.6	0

22	Baseline characteristics and effects of fingolimod on cognitive performance in patients with relapsing-remitting multiple sclerosis. <i>European Journal of Neurology</i> , 2021 , 28, 4135-4145	6	o
21	Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years.. <i>Multiple Sclerosis Journal</i> , 2022 , 13524585221079731	5	o
20	Multiple Sclerosis Severity Score (MSSS) improves the accuracy of individualized prediction in MS.. <i>Multiple Sclerosis Journal</i> , 2022 , 13524585221084577	5	o
19	Effects of teriflunomide treatment on cognitive performance and brain volume in patients with relapsing multiple sclerosis: Post hoc analysis of the TEMSO core and extension studies.. <i>Multiple Sclerosis Journal</i> , 2022 , 13524585221089534	5	o
18	Evaluation of no evidence of progression or active disease (nepad) in patients with primary progressive multiple sclerosis in the oratorio trial. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017 , 88, e1.85-e1	5.5	
17	EFFECT OF TERIFLUNOMIDE ON LYMPHOCYTE AND NEUTROPHIL COUNTS. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015 , 86, e4.25-e4	5.5	
16	Improving Accuracy of Brainstem MRI Volumetry: Effects of Age and Sex, and Normalization Strategies. <i>Frontiers in Neuroscience</i> , 2020 , 14, 609422	5.1	
15	PO114 Neda achievement by time interval with daclizumab. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017 , 88, A42.1-A42	5.5	
14	PO128 Infusion-related reactions with ocrelizumab in rms and ppms. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017 , 88, A46.1-A46	5.5	
13	What is new in MS spasticity research? Poster session highlights. <i>Neurodegenerative Disease Management</i> , 2015 , 5, 27-30	2.8	
12	BRAIN VOLUME CHANGE AND DISABILITY IN FINGOLIMOD TRIALS. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014 , 85, e4.44-e4	5.5	
11	Treating clinically isolated syndromes suggestive of MS [AuthorsNeply. <i>Lancet, The</i> , 2007 , 370, 2000-2004	4.0	
10	Muscle stiffness, gait instability, and liver cirrhosis in Wilson's disease. <i>Lancet, The</i> , 2020 , 396, 990	4.0	
9	Syndrome of inappropriate antidiuretic hormone secretion and hypothalamic hypocortisolism in neuromyelitis optica. <i>Lancet, The</i> , 2021 , 397, 2194	4.0	
8	085 Clinical outcomes were better for relapsing-remitting multiple sclerosis (RRMS) patients who remained on natalizumab compared to those who switched to oral or injectable therapies after 2 years in the tysabri observational program (TOP). <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018 , 89, A34.2-A34	5.5	
7	Effects of Dimethyl Fumarate on Brain Atrophy in Relapsing-Remitting Multiple Sclerosis: Pooled Analysis Phase 3 DEFINE and CONFIRM Studies.. <i>Frontiers in Neurology</i> , 2022 , 13, 809273	4.1	
6	021 Determinants of natalizumab-associated PML outcomes. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022 , 93, A20.1-A20	5.5	
5	034 Updated safety analysis of ocrelizumab in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022 , 93, A24.1-A24	5.5	

4	023 Relapse outcomes with natalizumab Q4W vs switch to Q6W. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022 , 93, A20.3-A21	5·5
3	018 Disease control beyond NEDA: the value of non-clinical measures to determine treatment response to natalizumab. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022 , 93, A19.1-A19	5·5
2	116 Serum immunoglobulin levels and infection risk in Phase 3 ofatumumab trials in relapsing multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022 , 93, A137.2-A137	5·5
1	020 Long-term efficacy of ocrelizumab in relapsing multiple sclerosis: 6 study years. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022 , 93, A19.3-A20	5·5